in*hale*a*bil*it*y

/inˈhālˈəˈbilədē/

“Having characteristics that allow respirable particles to follow the inhaled airstream deep into the lung.”

The ASERVO EQUIHALER is designed for inhaleABILITY for the management of severe equine asthma.

If clinical signs do not improve or worsen despite administration of ASERVO EQUIHALER, the prescriber should consider additional diagnostic evaluation.

Inhaleability

Designed to consistently deliver ciclesonide

  • Soft Mist™ Technology delivers medication in a slow-moving mist1
  • Pro-drug activated in the airway epithelium2
  • Activated prodrug has 12 times greater glucocorticoid receptor affinity than dexamethasone2
  • No statistically significant decrease in serum cortisol3, 4
  • Accepted by >93% of horses5
  • Proven safety and efficacy under controlled and field conditions in over 600 horses* 3,5,6

* Treated with ASERVO EQUIHALER or placebo.

In a large clinical field study, the most common adverse reactions reported were coughing, nasal discharge, sneezing, and nasal irritation/bleeding.

Features

What Makes ASERVO EQUIHALER unique

A combination of a novel glucocorticoid (ciclesonide) and advanced inhalation technology (Soft Mist™ Inhaler) designed specifically for horses with severe equine asthma.

A novel glucocorticoid that is activated in the lower airway into the potent anti- inflammatory des-ciclesonide for management of severe equiine asthma.
The Soft Mist™ Inhaler provides high fine-particle fraction for deep peripheral lung deposition, low velocity stream for easy inhalation and predetermined dosing for accurate delivery.
The nostril adapter fits gently inside the left nostril of the horse, while the BreathView® indicator allows the user to time the generation of the mist with the beginning of inhalation. The inhaler is ergonomically designed for left-hand use, allowing the right hand to remain free to comfort the horse.

Administration of glucocorticoids may worsen existing bacterial, fungal, or viral infection and may induce the first stage of parturition. Glucocorticoids should be used with caution in horses at a higher risk for laminitis. Do not use in horses with known hypersensitivity to ciclesonide or glucocorticoids.

Ciclesonide

The activated pro-drug is 12x as potent compared to dexamethasone2

close icon
Ciclesonide is
an inactive pro-drug
Activated to
des-ciclesonide
in the airway
Des-ciclesonide binds
to the glucocorticoid
receptors in the lungs
12x
more potent than dexamethasone2
No statistically significant effect on serum cortisol 3, 4

Administration of glucocorticoids may worsen existing bacterial, fungal, or viral infection. Secondary infections should be ruled out before prescribing ASERVO EQUIHALER. Inhaled glucocorticoids should be used with caution, if at all, in horses with active infection of the respiratory tract.

Soft Mist™

The Soft Mist™ Technology advantage

High fine-
particle fraction

>90% of particles in ASERVO EQUIHALER are <5µm in diameter

Optimal size for deep peripheral lung deposition

Low-velocity
stream

The mist in ASERVO EQUIHALER is released at low-velocity (0.8m/sec) for longer duration (>1 sec) 8

Easy to inhale
Validated in horses with severe equine asthma 3

Propellant-
free

Mechanical energy of the compressed spring generates the Soft Mist™

Propellant-free inhaler has lower carbon footprint compared to pMDI 9

Dosing
accuracy

Each actuation consistently delivers a predetermined dose

Consider appropriate wash out times prior to administering NSAIDs or additional glucocorticoids.

Soft Mist How the mist is made

Soft Mist™ Technology = small particle size × low velocity

Smaller, respirable particles (<5 microns) administered at low velocity travel with inhaled air deep into peripheral lung.10

Designed for Horses

Designed for horses with severe asthma


Not for use in humans. Keep this and all medications out of the reach of children. In case of accidental inhalation, seek medical advice immediately.

Designed for Horses Checklist

Easy to use

  • Nostril adapter
  • BreathView® breath indicator
  • Single use
  • Single-hand maneuver
  • Simple treatment protocol
  • Fill indicator

Designed for horses

  • Snug fit in the left nostril serves as reservoir for the drug
  • Easy timing with beginning of inhalation
  • Minimizes risk for cross-contamination between horses
  • Second hand is free to aid in handling the horse
  • One dose fits all
  • Easy monitoring of drug solution level
Acceptance
>93%
Well accepted by most horses 5
Compliance
>95%
High owner compliance 5

ASERVO® EQUIHALER®

Soft Mist™ is easily inhaled into the lower airway1

Local drug activity deep within the lung2

Proven safe3,4

Pro-drug reduces inflammation to decrease airway obstruction2

Accepted by >93% of horses5

Studied in over 600 horses under controlled and field conditions3,5,6

*Treated with ASERVO EQUIHALER or placebo.

Inhaled glucocorticoids should be used with caution, if at all, in horses with active infection of the respiratory tract. If clinical signs do not improve or worsen despite administration of ASERVO EQUIHALER, the prescriber should consider additional diagnostic evaluation.

For more information about the ASERVO EQUIHALER, contact a Boehringer Ingelheim representative.

IMPORTANT SAFETY INFORMATION: ASERVO EQUIHALER has not been evaluated in pregnant or lactating mares. In a large clinical field study, the most common adverse reactions reported were coughing, nasal discharge, sneezing and nasal irritation/bleeding. Administration of glucocorticoids may worsen existing bacterial, fungal, or viral infection and may induce the first stage of parturition. Glucocorticoids should be used with caution in horses at a higher risk for laminitis. Not for use in humans. Keep this and all medications out of the reach of children. In case of accidental inhalation, seek medical advice immediately. INFORMATION FOR HORSE OWNERS: After veterinary consultation, please read and understand the entire contents of the user manual for instructions regarding proper handling and use of ASERVO EQUIHALER.